Related Experiment Video
Updated: Sep 18, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Association of social vulnerability on time-to-treatment for patients with non-small cell lung cancer
Jonathan E Williams1, Faelan Jacobson-Davies2, Ryan C Jacobs3
1Department of Surgery, University of Michigan. Ann Arbor, MI, USA; Center for Healthcare Outcomes and Policy, University of Michigan. Ann Arbor, MI, USA.
Background:
For patients with early-stage non-small cell lung cancer (NSCLC), treatment delays confer worse overall survival. The relationship between social vulnerability and time-to-treatment for NSCLC is unknown.
Methods:
Using statewide cancer registry data, patients with localized (N0) NSCLC from 2015 to 2021 were identified. Social Vulnerability Index (SVI) was identified using patient place of residence. Using Poisson regression, the association of time-to-treatment and SVI was evaluated, with subgroup analyses stratifying by first treatment modality.
Results:
10,562 patients were included. Time-to-treatment increased in each subsequent SVI quartile. Compared to the lowest quartile, patients in the highest SVI quartile had longer adjusted time-to-treatment (64.6 vs 61.0 days, IRR 1.06 (95 % CI 1.05-1.07), p < 0.001). In subgroup analysis, patients in the highest quartile had longer time-to-treatment for all modalities.
Conclusions:
NSCLC patients with higher social vulnerability demonstrate longer time-to-treatment, motivating further work addressing social determinants of health to maximize population-level access to timely lung cancer care.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Related Concept Videos
02:56Treatment Resistant Cancers
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:20Comparing the Survival Analysis of Two or More Groups
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...